The aim of the study was to evaluate the safety and efficacy of using the new formulation
(Lipiodol-cisplatin suspension) for TACE in the treatment of HCC as compared to the
conventional formulation (Lipiodol-cisplatin emulsion). This is a prospective,
parallel-group, open-label randomized, phase II study that is conducted in accordance to the
Declaration of Helsinki and international standards of Good Clinical Practice, and approved
by the institutional review board. Eligible patients were randomized into either a treatment
arm of Lipiodol-cisplatin suspension or a control arm of Lipiodol-cisplatin emulsion with a
1:1 ratio.